ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
•02 Feb 2026 13:21

Shenzhen Zhaowei A/H Listing - Autos Thriving but Robotics Driving Share Price

Shenzhen Zhaowei Machinery & Electronics (003021 CH), is now looking to raise around US$300m in its A/H listing. We had looked at its past...

Logo
672 Views
Share
•02 Feb 2026 07:30

Montage Technology (6809 HK) IPO: Decent Upside Potential

​Montage Technology's 3-year EPS CAGR is projected to be 43.2%, with a fair price estimated at HK$147.4, a 20% premium over Rambus. This offers a...

Logo
709 Views
Share
•01 Feb 2026 10:15

A-H Premium Weekly (Jan 30th): China Railway, CNOOC, Ningbo Joyson Electronic, YOFC, Tianqi Lithium

We analyzed A-H premium changes in the past week and highlight A-H premium changes for China Railway, CNOOC, Ningbo Joyson Electronic, YOFC, Tianqi...

Logo
234 Views
Share
•30 Jan 2026 15:50

Montage Technology H Share Listing (6809 HK): Valuation Insights

The price momentum is strong amid a well-documented surge in memory chip prices. The proposed AH discount of 41.3% (based on the 29 January A Share...

Logo
717 Views
Share
bullish•Muyuan Foods Co
•30 Jan 2026 07:30

Muyuan Foods (2714 HK) IPO: Inexpensively Priced

​Muyuan's IPO offers good value due to its position as the world's largest hog farming company by capacity. It is valued at HK$46.90, with a floor...

Logo
543 Views
Share
x